In Minimally-Invasive Heart Valves, Edwards Cuts a Wide Swath

Heart valves used in surgical procedures constitute more than 40% of the revenues of Edwards Lifesciences. So the company's recent acquisition of endovascular heart valve company Percutaneous Valve Technologies Inc. (PVT), along with its earlier acquisition of a percutaneous heart valve from Jomed NV, could be regarded as part of its plan to launch a pre-emptive strike. Edwards now has the broadest and most advanced portfolio of endovascular heart valve repair products in the industry. It thus hedges itself against the possible future erosion of its surgical valve franchise by the new interventional cardiology-oriented approaches and beats out Medtronic and Boston Scientific, each of which previously held 10% stakes in PVT before the acquisition.

Heart valves used in surgical procedures constitute more than 40% of the revenues of Edwards Lifesciences Corp. , the world's leading manufacturer of tissue valves. So the company's recent acquisition of endovascular heart valve company Percutaneous Valve Technologies Inc. (PVT) for $125 million in cash plus $30 million in milestone payments, along with its earlier acquisition of a percutaneous heart valve from Jomed NV , could be regarded as part of its plan to launch a pre-emptive strike. [See Deal], [See Deal] Edwards Lifesciences now has the broadest and most advanced portfolio of endovascular heart valve repair products in the industry. It thus hedges itself against the possible future erosion of its surgical valve franchise by the new interventional cardiology-oriented approaches and beats out Medtronic Inc. and Boston Scientific Corp. , each of which previously held 10% stakes in PVT before the acquisition.

Edwards Lifesciences' Stuart Foster, corporate VP, technology and discovery, prefers to describe the company's efforts to develop new percutaneous technologies...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.